This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Regeneron files reply for injunction against Amgen in US cholesterol drug antitrust case

( July 14, 2025, 20:22 GMT | Official Statement) -- MLex Summary: Regeneron filed a reply in support of its request for a permanent injunction against Amgen regarding cholesterol-reducing medication, saying Amgen ignores the fact that a jury already found its anticompetitive conduct “broke the market.” Regeneron said that the proposed injunction addresses the conduct that the jury confirmed violated the law, foreclosing Regeneron from the market “intentionally” and “unreasonably,” and is necessary to restore and protect competition going forward.See attached file. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections